

Health & Social Care (HSC) Industry Partnership

Terms of Reference November 2020

The goal of the HSC Industry Partnership Agreement is to both develop and accelerate improvements to the health and wellbeing of patients affected by conditions under the care of the Health and Social Care System who are from all over the UK although predominantly from Northern Ireland (NI). Subsequently, our findings will be shared to benefit patients affected by these conditions more widely throughout both the UK and the world.

This goal will be best achieved through adopting a systematic approach to the improvement of health outcomes through the managed adoption of innovation – in diagnosis, treatment and coordination of care, underpinned by research and evaluation.

1. Purpose

The Medicines Optimisation Innovation Centre (MOIC) and the Association of the British Pharmaceutical Industry (ABPI) will convene a HSC Industry Steering Group to address the regional priorities for health conditions in NI, working together to introduce transformative medicines-related innovations across the HSC system, resulting in a triple win for patients, the service and the economy.

2 Shared Aims

The partners within the HSC Industry Partnership will work together to achieve the following aims:

- Rapid and consistent patient access to innovation
- More effective use of HSC resources
- Increased cross sector research collaboration
- Step change in the pace and consistency of adoption of evidence based innovative medicines and technologies

3. Approach

3.1 The HSC Industry Partnership will provide a joint forum for regular, ongoing interaction between the pharmaceutical industry and HSC to support achievement of the shared aims set out in 2 above.

The Partnership will formally meet at least three times per year.

The Partnership will enable identification areas of mutual interest to improve the diagnosis, treatment and care of patients.

The Partnership is an 'alliance of the willing'. All parties agree voluntarily to work together to achieve the shared vision of measurably improved outcomes for people affected by identified conditions.

3.2 The HSC Industry Partnership will create a 'Portal' process, acting as a conduit for collaborative proposals to improve the health outcomes for patients originating from all the partner organisations.

Through this process, as appropriate, the ABPI will ensure that such proposals are swiftly, fairly and transparently disseminated to ABPI member companies with an interest in the disease area in the form of 'Invitations to Respond'. This process will serve as a mechanism for partners to rapidly assess whether there is industry interest in developing collaborative initiatives at a formative stage.

4. Rationale for the HSC Industry Partnership

4.1: The Partnership was created in recognition of opportunities for NI to become a thriving health and life ecosystem to the benefits of patients, HSC and the economy. The opportunities will depend on effective stakeholder collaboration.

All partners acknowledge and fully support the wide range of legal and governance requirements that already exist to guide interaction between industry and the HSC. These include:

- 4.1.1 UK and EU Competition Law
- 4.1.2 ABPI Competition Law Guidance
- 4.1.3 PMCPA Code of Practice
- 4.1.4 ABPI / DH Guide to Joint Working
- 4.1.5 ABPI Disclosure UK Process
- 4.1.6 DH Guidance on working with Industry

5. Principles

5.1 All parties in the Partnership seek to deliver measurable improvements in outcomes through effective, trusted partnerships, which will support the adoption of innovation and the most efficient use of public money.

5.2 Collaborations arising from the Rare Disease Priority Delivery Group will be in accordance with the following principles:

- 5.2.1 Rigor – partnership work will be evidence-based and underpinned by transparent governance to ensure collaborations have a firm foundation.
- 5.2.2 Ambition – a shared goal of, driving evidence-based innovation into practice and generating evidence of the impact of innovation on patient outcomes.
- 5.2.3 Transparency – All proceedings undertaken and the results of all initiatives and collaborations, will be published when complete, subject to respecting commercial in confidence information.
- 5.2.4 Fairness – Initiatives undertaken will be conducted with equality of opportunity and appropriate access to all participants, companies and organisations.

6. Potential Areas for Collaboration in Year 1

6.1 Two potential areas of collaboration have been identified for Year 1

- 6.1.1 Improved treatment, management and prevention of Hepatitis C in NI.
- 6.1.2 Digitally enabling care

7. Governance

7.1 Professor Mike Scott, Director of MOIC and Colette Goldrick Executive Director Strategy & Partnerships ABPI, will jointly chair the Partnership.

7.2 Membership of the Group will include:

- 7.2.1 Chief Pharmaceutical Officer
- 7.2.2 HSC Representation from R&D, Data and Clinical Research
- 7.2.3 Local Patient/Local Parent and Carer of Patients/Patient Group representation
- 7.2.4 Deputy Chief Medical Officer for NI
- 7.2.5 Representation from Public Health Agency NI
- 7.2.6 HIRANI CEO
- 7.2.7 Public Affairs Manager ABPI
- 7.2.8 HSCB Director of Integrated Care

7.3 Accountability

The HSC Industry Partnership will be accountable to the Department of Health via the MOIC Board.

Annual Report: The Priority Delivery Group will publish a joint Annual Report in June each year.

Secretariat will be provided by ABPI, with meetings hosted virtually or in Antrim/Belfast.

8. Confidentiality and information governance

8.1 In the course of its operation information may be shared which is commercial in confidence. All members of the HSC Industry Partnership undertake to respect this and not to share beyond necessary parties. All parties acknowledge that antitrust regulations must be respected in relation to the sharing of information between commercial organisations and other industry parties.

9 Deliverables and milestones

The HSC Industry Partnership will agree a priority work programme by March 2021.

Each project will not be supported without clear and agreed Project Documentation setting out measurable aims, ways of working, organisational responsibilities, and accountability, timelines and clear project management etc.

10 Review period

The HSC Industry Partnership will be reviewed annually.

Next review date Dec 2021